O. Hiranuma

发表

Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

T. Kijima, K. Takayama, J. Uchino, 2022, Diagnostics.

Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study

T. Kijima, K. Takayama, J. Uchino, 2021, Oncoimmunology.

Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients

K. Takayama, J. Uchino, K. Morimoto, 2021, Journal of Cancer Research and Clinical Oncology.

Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study

T. Kijima, K. Takayama, J. Uchino, 2021, Journal of Cancer Research and Clinical Oncology.

Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study

K. Takayama, K. Morimoto, Tadaaki Yamada, 2021, Thoracic cancer.

Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients

K. Takayama, J. Uchino, K. Morimoto, 2020, Medical Oncology.

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations

K. Takayama, J. Uchino, Tadaaki Yamada, 2018, BMC Cancer.

Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients

K. Takayama, J. Uchino, Tadaaki Yamada, 2020, Scientific Reports.

Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer

K. Takayama, J. Uchino, Tadaaki Yamada, 2019, Journal of clinical medicine.

Pathogenicity of Mycolicibacterium phlei, a non-pathogenic nontuberculous mycobacterium in an immunocompetent host carrying anti-interferon gamma autoantibodies: a case report

Y. Hoshino, T. Sakagami, H. Fukano, 2019, BMC Infectious Diseases.

Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study

K. Takayama, Tadaaki Yamada, Shinsaku Tokuda, 2022, JTO clinical and research reports.

Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study).

K. Takayama, J. Uchino, Tadaaki Yamada, 2019, Clinical lung cancer.

Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study

S. Yano, K. Takayama, J. Uchino, 2021, Translational lung cancer research.

Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study

K. Takayama, J. Uchino, Tadaaki Yamada, 2021, Translational lung cancer research.

Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study

K. Takayama, Tadaaki Yamada, H. Yoshioka, 2022, Frontiers in Oncology.

The Impact of Immune-related Adverse Events on the Effect of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer

K. Takayama, J. Uchino, Tadaaki Yamada, 2019, Haigan.

Bradykinin Inhibits Serum-Depletion-Induced Apoptosis of Human Vascular Endothelial Cells by Inducing Nitric Oxide via Calcium Ion Kinetics

K. Nakagawa, M. Nakagawa, S. Sawada, 2002, Journal of cardiovascular pharmacology.

Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan

K. Takayama, Y. Hasegawa, J. Uchino, 2022, Journal of Thoracic Oncology.

Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients

K. Takayama, J. Uchino, Tadaaki Yamada, 2021, Journal of Cancer Research and Clinical Oncology.

Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study

T. Kijima, K. Takayama, J. Uchino, 2021, Journal of Cancer Research and Clinical Oncology.

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial

K. Takayama, J. Uchino, M. Hibino, 2022, JTO clinical and research reports.

Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations

T. Kondo, J. Uchino, Rei Noguchi, 2023, Proteomes.

High levels of AXL expression in untreated EGFR ‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib

T. Mitsudomi, S. Yano, K. Takayama, 2022, Cancer science.

Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment

T. Ishizuka, H. Uramoto, M. Kawasaki, 2020, Journal of clinical medicine.

An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer

K. Takayama, J. Uchino, Tadaaki Yamada, 2018, Medicine.

K. Takayama, J. Uchino, K. Morimoto, 2021, Frontiers in Oncology.

Effect of Cicletanine on the Nitric Oxide Pathway in Human Umbilical Vein Endothelial Cells

M. Nakagawa, S. Sawada, H. Tsuji, 2001, Journal of cardiovascular pharmacology.

Hepatic AngiomyolipomaAssociated with Splenic Hamartoma

M. Bamba, Irie, O. Hiranuma, 2007 .

Hepatic angiomyolipoma associated with splenic hamartoma.

M. Bamba, O. Hiranuma, T. Shigematsu, 2002, Internal medicine.

Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer.

T. Kijima, K. Takayama, J. Uchino, 2021, Lung cancer.

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation

K. Takayama, J. Uchino, Tadaaki Yamada, 2019, Cancers.

Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer

Young Hak Kim, K. Takayama, K. Azuma, 2023, Cancer Immunology, Immunotherapy.

Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial

J. Uchino, H. Kimura, K. Yoshimura, 2023, The oncologist.

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC

K. Takayama, K. Azuma, Tadaaki Yamada, 2022, JTO clinical and research reports.

Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer

Tadaaki Yamada, Y. Kaneko, Shinsaku Tokuda, 2023, Supportive Care in Cancer.

Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M‐Positive Non‐Small‐Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial

T. Ishizuka, H. Uramoto, M. Kawasaki, 2019, The oncologist.